These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16545633)

  • 21. Tubulin: an example of targeted chemotherapy.
    Seligmann J; Twelves C
    Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Inhibitors of microtubule polymerization- new natural compounds as potential anti-cancer drugs].
    Rogalska A; Miśkiewicz K; Marczak A
    Postepy Hig Med Dosw (Online); 2015 May; 69():571-85. PubMed ID: 25983296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
    Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
    J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
    Bhattacharyya B; Panda D; Gupta S; Banerjee M
    Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indole, a core nucleus for potent inhibitors of tubulin polymerization.
    Brancale A; Silvestri R
    Med Res Rev; 2007 Mar; 27(2):209-38. PubMed ID: 16788980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
    Perez EA
    Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
    Chen YC; Lu PH; Pan SL; Teng CM; Kuo SC; Lin TP; Ho YF; Huang YC; Guh JH
    Biochem Pharmacol; 2007 Jun; 74(1):10-9. PubMed ID: 17475221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics.
    Kanakkanthara A; Teesdale-Spittle PH; Miller JH
    Anticancer Agents Med Chem; 2013 Jan; 13(1):147-58. PubMed ID: 22583426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential mechanisms of resistance to microtubule inhibitors.
    Kavallaris M; Annereau JP; Barret JM
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
    Aparicio LM; Pulido EG; Gallego GA
    Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.
    Buey RM; Barasoain I; Jackson E; Meyer A; Giannakakou P; Paterson I; Mooberry S; Andreu JM; Díaz JF
    Chem Biol; 2005 Dec; 12(12):1269-79. PubMed ID: 16356844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Towards modern anticancer agents that interact with tubulin.
    La Regina G; Coluccia A; Naccarato V; Silvestri R
    Eur J Pharm Sci; 2019 Apr; 131():58-68. PubMed ID: 30690185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding.
    Gupta KK; Bharne SS; Rathinasamy K; Naik NR; Panda D
    FEBS J; 2006 Dec; 273(23):5320-32. PubMed ID: 17069615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions of antimitotic peptides and depsipeptides with tubulin.
    Hamel E
    Biopolymers; 2002; 66(3):142-60. PubMed ID: 12385035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.
    Katsetos CD; Dráberová E; Legido A; Dumontet C; Dráber P
    J Cell Physiol; 2009 Dec; 221(3):505-13. PubMed ID: 19650075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytotoxic activity and cytostatic mechanism of novel 2-arylbenzo[b]furans.
    Yang H; Pang JY; Cai YC; Xu ZL; Xian LJ
    J Pharm Pharmacol; 2006 Sep; 58(9):1281-7. PubMed ID: 16945188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of 4-arylcoumarin analogues of combretastatins with microtubule network of HBL100 cells and binding to tubulin.
    Rappl C; Barbier P; Bourgarel-Rey V; Grégoire C; Gilli R; Carre M; Combes S; Finet JP; Peyrot V
    Biochemistry; 2006 Aug; 45(30):9210-8. PubMed ID: 16866367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imidazoles and benzimidazoles as tubulin-modulators for anti-cancer therapy.
    Torres FC; García-Rubiño ME; Lozano-López C; Kawano DF; Eifler-Lima VL; von Poser GL; Campos JM
    Curr Med Chem; 2015; 22(11):1312-23. PubMed ID: 25620093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epothilones: mechanism of action and biologic activity.
    Goodin S; Kane MP; Rubin EH
    J Clin Oncol; 2004 May; 22(10):2015-25. PubMed ID: 15143095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.